Multiparametric assay using HepaRG cells for predicting drug-induced liver injury

Toxicology Letters

Volumn 236, Issue 1, 2015, Pages 16-24

  Tomida, Takafumi ^a   Okamura, Hayao ^a   Satsukawa, Masahiro ^a   Yokoi, Tsuyoshi ^b   Konno, Yoshihiro ^a  

^a KAKEN PHARMACEUTICAL CO LTD   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug induced liver injury; HepaRG cells; Multiparametric assay

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; AMIODARONE; ASCORBIC ACID; BROMFENAC; CAFFEINE; CASPASE 3; CASPASE 7; CHLORPROMAZINE; CYCLOSPORIN A; DICLOFENAC; FAMOTIDINE; FLUTAMIDE; FUROSEMIDE; GLUTATHIONE; IBUPROFEN; ISONIAZID; KETOCONAZOLE; LACTATE DEHYDROGENASE; LOSARTAN POTASSIUM; MICONAZOLE NITRATE; OLANZAPINE; PARACETAMOL; TAMOXIFEN; TETRACYCLINE; TICLOPIDINE; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; ALB PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASP7 PROTEIN, HUMAN; NEW DRUG; SERUM ALBUMIN;

ARTICLE; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPARG CELL LINE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID STORAGE; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TOXIC HEPATITIS; TREATMENT DURATION; BIOLOGICAL MODEL; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CLASSIFICATION; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; LIPID METABOLISM; METABOLISM; OSMOLARITY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SECRETION (PROCESS); TUMOR CELL LINE;

CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; DRUGS, INVESTIGATIONAL; GLUTATHIONE; HEPATOCYTES; HUMANS; LIPID METABOLISM; MODELS, BIOLOGICAL; OSMOLAR CONCENTRATION; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; ROC CURVE; SERUM ALBUMIN;

EID: 84928726285     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2015.04.014     Document Type: Article

References (45)

1. Al-Salman J., Arjomand H., Kemp D.G., Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann. Intern. Med. 2000, 132:121-124.
2. Alam I., Ferrell L.D., Bass N.M. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am. J. Gastroenterol. 1996, 91:1626-1630.
3. Aninat C., Piton A., Glaise D., Le Charpentier T., Langouët S., Morel F., Guguen-Guillouzo C., Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. 2006, 34:75-83.
4. Anthérieu S., Bachour-El Azzi P., Dumont J., Abdel-Razzak Z., Guguen-Guillouzo C., Fromenty B., Robin M.A., Guillouzo A. Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells. Hepatology 2013, 57:1518-1529.
5. Anthérieu S., Chesné C., Li R., Guguen-Guillouzo C., Guillouzo A. Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol. In Vitro 2012, 26:1278-1285.
6. Anthérieu S., Rogue A., Fromenty B., Guillouzo A., Robin M.A. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 2011, 53:1895-1905.
7. Badcock N.R., Bartholomeusz F.D., Frewin D.B., Sansom L.N., Reid J.G. The pharmacokinetics of ketoconazole after chronic administration in adults. Eur. J. Clin. Pharmacol. 1987, 33:531-534.
8. Cerec V., Glaise D., Garnier D., Morosan S., Turlin B., Drenou B., Gripon P., Kremsdorf D., Guguen-Guillouzo C., Corlu A. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007, 45:957-967.
9. Chen M., Vijay V., Shi Q., Liu Z., Fang H., Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 2011, 16:697-703.
10. Floyd J.S., Barbehenn E., Lurie P., Wolfe S.M. Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol. Drug. Saf. 2009, 18:1238-1243.
11. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 1995, 67:101-154.
12. Fréneaux E., Labbe G., Letteron P., The Le Dinh, Degott C., Genève J., Larrey D., Pessayre D. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988, 8:1056-1062.
13. Garside H., Marcoe K.F., Chesnut-Speelman J., Foster A.J., Muthas D., Kenna J.G., Warrior U., Bowes J., Baumgartner J. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes. Toxicol. In Vitro 2014, 28:171-181.
14. Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., Guyomard C., Lucas J., Trepo C., Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15655-15660.
15. Guguen-Guillouzo C., Guillouzo A. General review on in vitro hepatocyte models and their applications. Methods Mol. Biol. 2010, 640:1-40.
16. Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 2007, 168:66-73.
17. Gustafsson F., Foster A.J., Sarda S., Bridgland-Taylor M.H., Kenna J.G. A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. Toxicol. Sci. 2014, 137:189-211.
18. Gómez-Lechón M.J., O'Connor J.E., Lahoz A., Castell J.V., Donato M.T. Identification of apoptotic drugs: multiparametric evaluation in cultured hepatocytes. Curr. Med. Chem. 2008, 15:2071-2085.
19. Gómez-Lechón M.J., Tolosa L., Castell J.V., Donato M.T. Mechanism-based selection of compounds for the development of innovative in vitro approaches to hepatotoxicity studies in the LIINTOP project. Toxicol. In Vitro 2010, 24:1879-1889.
20. Gómez-Lechón M.J., Tolosa L., Conde I., Donato M.T. Competency of different cell models to predict human hepatotoxic drugs. Expert Opin. Drug Metab. Toxicol. 2014, 10:1553-1568.
21. Hewitt N.J., Lechón M.J., Houston J.B., Hallifax D., Brown H.S., Maurel P., Kenna J.G., Gustavsson L., Lohmann C., Skonberg C., Guillouzo A., Tuschl G., Li A.P., LeCluyse E., Groothuis G.M., Hengstler J.G. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 2007, 39:159-234.
22. Javier Rodríguez-González F., Montero J.L., Puente J., Fraga E., Costán G., Barrera P., Muntané J., De la Mata M., Zambrana J.L. Orthotopic liver transplantation after subacute liver failure induced by therapeutic doses of ibuprofen. Am. J. Gastroenterol. 2002, 97:2476-2477.
23. Jones H.M., Parrott N., Jorga K., Lavé T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 2006, 45:511-542.
24. Khetani S.R., Kanchagar C., Ukairo O., Krzyzewski S., Moore A., Shi J., Aoyama S., Aleo M., Will Y. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol. Sci. 2013, 132:107-117.
25. Lambert C.B., Spire C., Claude N., Guillouzo A. Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol. Appl. Pharmacol. 2009, 234:345-360.
26. LeCluyse E.L. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci. 2001, 13:343-368.
27. Lin Z., Will Y. Evaluation of drugs with specific organ toxicities in organ-specific cell lines. Toxicol. Sci. 2012, 126:114-127.
28. McGill M.R., Yan H.M., Ramachandran A., Murray G.J., Rollins D.E., Jaeschke H. HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology 2011, 53:974-982.
29. Mitchell M., Riesenberg R., Bari M.A., Marquez E., Kurtz D., Falk D., Hardy T., Taylor C.C., Mitchell C.P., Cavazzoni P. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40mg/d oral olanzapine relative to 20mg/d oral olanzapine in stable psychiatric subjects. Clin. Ther. 2006, 28:881-892.
30. O'Brien P.J., Irwin W., Diaz D., Howard-Cofield E., Krejsa C.M., Slaughter M.R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P., Hougham C. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80:580-604.
31. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 2000, 32:56-67.
32. Persson M., Løye A.F., Mow T., Hornberg J.J. A high content screening assay to predict human drug-induced liver injury during drug discovery. J. Pharmacol. Toxicol. Methods 2013, 68:302-313.
33. Porceddu M., Buron N., Roussel C., Labbe G., Fromenty B., Borgne-Sanchez A. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol. Sci. 2012, 129:332-345.
34. Poulin P., Jones R.D., Jones H.M., Gibson C.R., Rowland M., Chien J.Y., Ring B.J., Adkison K.K., Ku M.S., He H., Vuppugalla R., Marathe P., Fischer V., Dutta S., Sinha V.K., Björnsson T., Lavé T., Yates J.W. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J. Pharm. Sci. 2011, 100:4127-4157.
35. Rodrigues R.M., Bouhifd M., Bories G., Sacco M.G., Gribaldo L., Fabbri M., Coecke S., Whelan M.P. Assessment of an automated in vitro basal cytotoxicity test system based on metabolically-competent cells. Toxicol. In Vitro 2013, 27:760-767.
36. Russmann S., Kullak-Ublick G.A., Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem. 2009, 16:3041-3053.
37. Soldatow V.Y., Lecluyse E.L., Griffith L.G., Rusyn I. In vitro models for liver toxicity testing. Toxicol. Res. (Camb.) 2013, 2:23-39.
38. Sternlieb P., Robinson R.M. Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen. N. Y. State J. Med. 1978, 78:1239-1243.
39. Tolosa L., Pinto S., Donato M.T., Lahoz A., Castell J.V., O'Connor J.E., Gómez-Lechón M.J. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol. Sci. 2012, 127:187-198.
40. Turnbull D.M., Rawlins M.D., Weightman D., Chadwick D.W. Plasma concentrations of sodium valproate: their clinical value. Ann. Neurol. 1983, 14:38-42.
41. Usui T., Mise M., Hashizume T., Yabuki M., Komuro S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab. Dispos. 2009, 37:2383-2392.
42. Watkins P.B. Drug safety sciences and the bottleneck in drug development. Clin. Pharmacol. Ther. 2011, 89:788-790.
43. Xu J.J., Diaz D., O'Brien P.J. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem. Biol. Interact. 2004, 150:115-128.
44. Xu J.J., Henstock P.V., Dunn M.C., Smith A.R., Chabot J.R., de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 2008, 105:97-105.
45. Youden W.J. Index for rating diagnostic tests. Cancer 1950, 3:32-35.